Skip to main content

Table 7 Gemcitabine and difluorodeoxyuridine plasma Cmax, AUC and half life in patients (n=7) given gemcitabine 800 mg/m 2 with PR-104. (Mean ± standard deviation)

From: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

 

Cmax (mg/L)

AUC (mg/L*hr)

t1/2(hr)

Gemcitabine

20.8 ± 10.6

4.87 ± 1.69

0.21 ± 0.06

Difluorodeoxyuridine

30.8 ± 9.56

219 ± 57.6

12.2 ± 2.34

  1. a Values and mean ± SEM.